share_log

Transcode Therapeutics | CORRESP: CORRESP

SEC announcement ·  Jan 17 11:31
Summary by Moomoo AI
TransCode Therapeutics, Inc., a biotech company listed under the ticker RNAZ.US, has moved to accelerate the effective date of its registration statement on Form S-1, as per a correspondence with the U.S. Securities and Exchange Commission (SEC) dated January 17, 2024. The placement agent, H.C. Wainwright & Co., LLC, has concurred with TransCode's request to advance the effective date to 5:15 P.M. Eastern Time on the same day, or as soon as practicable thereafter. This acceleration is in accordance with Rule 461 under the Securities Act. H.C. Wainwright & Co., acting solely as a placement agent on a best-efforts basis for the offering, acknowledges its obligations under the Securities Act in relation to the offering.
TransCode Therapeutics, Inc., a biotech company listed under the ticker RNAZ.US, has moved to accelerate the effective date of its registration statement on Form S-1, as per a correspondence with the U.S. Securities and Exchange Commission (SEC) dated January 17, 2024. The placement agent, H.C. Wainwright & Co., LLC, has concurred with TransCode's request to advance the effective date to 5:15 P.M. Eastern Time on the same day, or as soon as practicable thereafter. This acceleration is in accordance with Rule 461 under the Securities Act. H.C. Wainwright & Co., acting solely as a placement agent on a best-efforts basis for the offering, acknowledges its obligations under the Securities Act in relation to the offering.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more